Keywords
Last Name
Institution

Maria F Lopes-Virella

Title
InstitutionMedical University of South Carolina
DepartmentEndocrinology
AddressP.O. Box MSC 776
STB 529
Thurmond Gazes - 30 Courtenay Drive
Phone843-789-6823
Fax843-789-6854
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Kidney, Diabetes

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lopes-Virella MF, Bebu I, Hunt KJ, Virella G, Baker NL, Braffett B, Gao X, Lachin JM. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 Jun 19. PMID: 31217176.
      View in: PubMed
    2. Basu A, Bebu I, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Budoff MJ, Alaupovic P, Lyons TJ. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in type 1 diabetes. J Lipid Res. 2019 Jun 15. PMID: 31203233.
      View in: PubMed
    3. Lopes-Virella MF, Baker NL, Hunt KJ, Hammad SM, Arthur J, Virella G, Klein RL. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019 May - Jun; 13(3):481-491.e1. PMID: 31043336.
      View in: PubMed
    4. Clayton S, Cauble E, Kumar A, Patil N, Ledford D, Kolliputi N, Lopes-Virella MF, Castell D, Richter J. Plasma levels of TNF-a, IL-6, IFN-?, IL-12, IL-17, IL-22, and IL-23 in achalasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD). BMC Gastroenterol. 2019 Feb 11; 19(1):28. PMID: 30744559.
      View in: PubMed
    5. Lopes-Virella MF, Virella G. Modified LDL Immune Complexes and Cardiovascular Disease. Curr Med Chem. 2019; 26(9):1680-1692. PMID: 29792135.
      View in: PubMed
    6. Lu Z, Li Y, Ru JH, Lopes-Virella MF, Lyons TJ, Huang Y. Interaction of palmitate and LPS regulates cytokine expression and apoptosis through sphingolipids in human retinal microvascular endothelial cells. Exp Eye Res. 2019 01; 178:61-71. PMID: 30273577.
      View in: PubMed
    7. Li Y, Lu Z, Ru JH, Lopes-Virella MF, Lyons TJ, Huang Y. Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro. Am J Physiol Endocrinol Metab. 2018 Nov 01; 315(5):E745-E757. PMID: 29989851.
      View in: PubMed
    8. Jin J, Lu Z, Li Y, Ru JH, Lopes-Virella MF, Huang Y. LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol. 2018 10; 104(4):843-853. PMID: 29882996.
      View in: PubMed
    9. Conway BN, Lopes-Virella MF, Blot WJ. Late adulthood mortality among African-American and white American people with Type 1 diabetes according to age at diabetes diagnosis. Diabet Med. 2018 06; 35(6):729-736. PMID: 29532512.
      View in: PubMed
    10. Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 05; 59(5):872-883. PMID: 29576550.
      View in: PubMed
    11. Jin J, Lu Z, Li Y, Cowart LA, Lopes-Virella MF, Huang Y. Docosahexaenoic acid antagonizes the boosting effect of palmitic acid on LPS inflammatory signaling by inhibiting gene transcription and ceramide synthesis. PLoS One. 2018; 13(2):e0193343. PMID: 29474492.
      View in: PubMed
    12. Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA. Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. Diabetes Care. 2018 04; 41(4):840-846. PMID: 29382658.
      View in: PubMed
    13. Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, Lopes-Virella MF. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135. PMID: 29118060.
      View in: PubMed
    14. Lu Z, Li Y, Brinson CW, Lopes-Virella MF, Huang Y. Cooperative stimulation of atherogenesis by lipopolysaccharide and palmitic acid-rich high fat diet in low-density lipoprotein receptor-deficient mice. Atherosclerosis. 2017 10; 265:231-241. PMID: 28934649.
      View in: PubMed
    15. Virella G, Wilson K, Elkes J, Hammad SM, Rajab HA, Li Y, Chassereau C, Huang Y, Lopes-Virella M. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018 02; 187:1-9. PMID: 28689783.
      View in: PubMed
    16. Lu Z, Li Y, Brinson CW, Kirkwood KL, Lopes-Virella MF, Huang Y. CD36 is upregulated in mice with periodontitis and metabolic syndrome and involved in macrophage gene upregulation by palmitate. Oral Dis. 2017 Mar; 23(2):210-218. PMID: 27753178.
      View in: PubMed
    17. Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane B, Montgomery J, Chimowitz MI. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24; 88(4):379-385. PMID: 28003500.
      View in: PubMed
    18. Lee MH, Appleton KM, El-Shewy HM, Sorci-Thomas MG, Thomas MJ, Lopes-Virella MF, Luttrell LM, Hammad SM, Klein RL. S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization. J Lipid Res. 2017 02; 58(2):325-338. PMID: 27881715.
      View in: PubMed
    19. Brinson CW, Lu Z, Li Y, Lopes-Virella MF, Huang Y. Lipopolysaccharide and IL-1ß coordinate a synergy on cytokine production by upregulating MyD88 expression in human gingival fibroblasts. Mol Immunol. 2016 11; 79:47-54. PMID: 27697591.
      View in: PubMed
    20. Orchard TJ, Backlund JC, Costacou T, Cleary P, Lopes-Virella M, Levy AP, Lachin JM. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complications. 2016 Nov - Dec; 30(8):1577-1584. PMID: 27539884.
      View in: PubMed
    21. Li Y, Lu Z, Huang Y, Lopes-Virella MF, Virella G. F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice. Clin Immunol. 2016 Dec; 173:50-56. PMID: 27455858.
      View in: PubMed
    22. Hammad SM, Baker NL, El Abiad JM, Spassieva SD, Pierce JS, Rembiesa B, Bielawski J, Lopes-Virella MF, Klein RL. Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study. Neuromolecular Med. 2017 Mar; 19(1):46-56. PMID: 27388466.
      View in: PubMed
    23. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9. PMID: 26861948.
      View in: PubMed
    24. Zhang Y, Jenkins AJ, Basu A, Stoner JA, Lopes-Virella MF, Klein RL. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7. PMID: 26658239.
      View in: PubMed
    25. Jaffa MA, Luttrell D, Schmaier AH, Klein RL, Lopes-Virella M, Luttrell LM, Jaffa AA. Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes. 2016 Feb; 65(2):498-502. PMID: 26603531.
      View in: PubMed
    26. Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein RL, Lopes-Virella MF, Timothy Garvey W, Lyons TJ. Data on carotid intima-media thickness and lipoprotein subclasses in type 1 diabetes from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Data Brief. 2016 Mar; 6:33-8. PMID: 26759826.
      View in: PubMed
    27. Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016 Jan; 244:93-100. PMID: 26600440.
      View in: PubMed
    28. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF, Wierzbicki AS. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 01; 132(22):2167-92. PMID: 26510694.
      View in: PubMed
    29. Lu Z, Zhang X, Li Y, Lopes-Virella MF, Huang Y. TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. Immunobiology. 2015 Nov; 220(11):1246-54. PMID: 26162692.
      View in: PubMed
    30. Hunt KJ, Baker NL, Cleary PA, Klein R, Virella G, Lopes-Virella MF. Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort. Diabetes Care. 2015 Jul; 38(7):1281-9. PMID: 25852210.
      View in: PubMed
    31. Li Y, Lu Z, Zhang X, Yu H, Kirkwood KL, Lopes-Virella MF, Huang Y. Metabolic syndrome exacerbates inflammation and bone loss in periodontitis. J Dent Res. 2015 Feb; 94(2):362-70. PMID: 25503900.
      View in: PubMed
    32. Turan TN, Rumboldt Z, Granholm AC, Columbo L, Welsh CT, Lopes-Virella MF, Spampinato MV, Brown TR. Intracranial atherosclerosis: correlation between in-vivo 3T high resolution MRI and pathology. Atherosclerosis. 2014 Dec; 237(2):460-3. PMID: 25463074.
      View in: PubMed
    33. Rajab HA, Baker NL, Hunt KJ, Klein R, Cleary PA, Lachin J, Virella G, Lopes-Virella MF. The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. J Diabetes Complications. 2015 Jan-Feb; 29(1):108-14. PMID: 25441222.
      View in: PubMed
    34. Virella G, Lopes-Virella MF. The role of the immune system in the pathogenesis of diabetic complications. Front Endocrinol (Lausanne). 2014; 5:126. PMID: 25126086.
      View in: PubMed
    35. Basu A, Jenkins AJ, Stoner JA, Thorpe SR, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis. 2014 Sep; 236(1):188-195. PMID: 25063949.
      View in: PubMed
    36. Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014 Oct; 63(10):1287-95. PMID: 25088746.
      View in: PubMed
    37. Fu D, Yu JY, Wu M, Du M, Chen Y, Abdelsamie SA, Li Y, Chen J, Boulton ME, Ma JX, Lopes-Virella MF, Virella G, Lyons TJ. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res. 2014 May; 55(5):860-9. PMID: 24616481.
      View in: PubMed
    38. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G. Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e108-9. PMID: 24496801.
      View in: PubMed
    39. Jenkins AJ, Fu D, Azar M, Stoner JA, Kaufman DG, Zhang S, Klein RL, Lopes-Virella MF, Ma JX, Lyons TJ. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014 May-Jun; 28(3):353-9. PMID: 24560422.
      View in: PubMed
    40. Jin J, Machado ER, Yu H, Zhang X, Lu Z, Li Y, Lopes-Virella MF, Kirkwood KL, Huang Y. Simvastatin inhibits LPS-induced alveolar bone loss during metabolic syndrome. J Dent Res. 2014 Mar; 93(3):294-9. PMID: 24352501.
      View in: PubMed
    41. Lu Z, Li Y, Samuvel DJ, Jin J, Zhang X, Lopes-Virella MF, Huang Y. MD-2 is involved in the stimulation of matrix metalloproteinase-1 expression by interferon-? and high glucose in mononuclear cells - a potential role of MD-2 in Toll-like receptor 4-independent signalling. Immunology. 2013 Nov; 140(3):301-13. PMID: 23800176.
      View in: PubMed
    42. Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec; 231(2):315-22. PMID: 24267245.
      View in: PubMed
    43. Jin J, Zhang X, Lu Z, Li Y, Lopes-Virella MF, Yu H, Haycraft CJ, Li Q, Kirkwood KL, Huang Y. Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease. J Periodontal Res. 2014 Aug; 49(4):518-26. PMID: 24117880.
      View in: PubMed
    44. Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013; 20(10):743-54. PMID: 23965492.
      View in: PubMed
    45. Azar M, Lyons TJ, Alaupovic P, Stoner JA, Quiroga C, Kaufman DG, Lopes-Virella M, Klein RL, Jenkins AJ. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Nov-Dec; 27(6):627-32. PMID: 23911536.
      View in: PubMed
    46. Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Sep-Oct; 27(5):447-53. PMID: 23850262.
      View in: PubMed
    47. Bhensdadia NM, Hunt KJ, Lopes-Virella MF, Michael Tucker J, Mataria MR, Alge JL, Neely BA, Janech MG, Arthur JM. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes. Kidney Int. 2013 Jun; 83(6):1136-43. PMID: 23536133.
      View in: PubMed
    48. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23. PMID: 23514730.
      View in: PubMed
    49. Virella G, Colglazier J, Chassereau C, Hunt KJ, Baker NL, Lopes-Virella MF. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74. PMID: 23323982.
      View in: PubMed
    50. Turan TN, Lynn MJ, Nizam A, Lane B, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Benavente O, White CL, Brown WV, Caskey MF, Steiner MR, Vilardo N, Stufflebean A, Derdeyn CP, Fiorella D, Janis S, Chimowitz MI. Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e51-60. PMID: 22991350.
      View in: PubMed
    51. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31. PMID: 22963984.
      View in: PubMed
    52. Virella G, Lopes-Virella MF. The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes. Front Endocrinol (Lausanne). 2012; 3:76. PMID: 22715334.
      View in: PubMed
    53. Lu Z, Li Y, Jin J, Zhang X, Lopes-Virella MF, Huang Y. Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleukin-6. Arterioscler Thromb Vasc Biol. 2012 Jul; 32(7):1696-706. PMID: 22596222.
      View in: PubMed
    54. Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM. Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology. 2012 May; 136(1):30-45. PMID: 22236141.
      View in: PubMed
    55. Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40. PMID: 22511260.
      View in: PubMed
    56. Jin J, Sundararaj KP, Samuvel DJ, Zhang X, Li Y, Lu Z, Lopes-Virella MF, Huang Y. Different signaling mechanisms regulating IL-6 expression by LPS between gingival fibroblasts and mononuclear cells: seeking the common target. Clin Immunol. 2012 May; 143(2):188-99. PMID: 22386866.
      View in: PubMed
    57. Jin J, Samuvel DJ, Zhang X, Li Y, Lu Z, Lopes-Virella MF, Huang Y. Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol. 2011 Dec; 49(3):423-32. PMID: 22030478.
      View in: PubMed
    58. Samuvel DJ, Jin J, Sundararaj KP, Li Y, Zhang X, Lopes-Virella MF, Huang Y. TLR4 activation and IL-6-mediated cross talk between adipocytes and mononuclear cells synergistically stimulate MMP-1 expression. Endocrinology. 2011 Dec; 152(12):4662-71. PMID: 21952248.
      View in: PubMed
    59. Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23. PMID: 21856760.
      View in: PubMed
    60. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011 Aug; 58(2):157-66. PMID: 21558879.
      View in: PubMed
    61. Schuyler CA, Ta NN, Li Y, Lopes-Virella MF, Huang Y. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. J Endocrinol. 2011 Jul; 210(1):37-46. PMID: 21478228.
      View in: PubMed
    62. Abdelsamie SA, Li Y, Huang Y, Lee MH, Klein RL, Virella G, Lopes-Virella MF. Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III. Clin Immunol. 2011 Jun; 139(3):258-66. PMID: 21439910.
      View in: PubMed
    63. Brown WV, Goldberg RB, Lopes-Virella M, Reaven P. Reducing vascular disease risk in the type 2 diabetic patient. J Clin Lipidol. 2011 Jan-Feb; 5(1):3-11. PMID: 21262501.
      View in: PubMed
    64. Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011 Feb; 214(2):462-7. PMID: 21156319.
      View in: PubMed
    65. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011 Feb; 60(2):582-9. PMID: 20980456.
      View in: PubMed
    66. Al Gadban MM, Smith KJ, Soodavar F, Piansay C, Chassereau C, Twal WO, Klein RL, Virella G, Lopes-Virella MF, Hammad SM. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010 Sep 02; 5(9). PMID: 20824093.
      View in: PubMed
    67. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec; 213(2):429-35. PMID: 20843518.
      View in: PubMed
    68. Jaffa MA, Woolson RF, Lipsitz SR, Baliga PK, Lopes-Virella M, Lackland DT. Analyses of renal outcome following transplantation adjusting for informative right censoring and demographic factors: A longitudinal study. Ren Fail. 2010 Jul; 32(6):691-8. PMID: 20540637.
      View in: PubMed
    69. Klein RL, Carter RE, Jenkins AJ, Lyons TJ, Baker NL, Gilbert GE, Virella G, Lopes-Virella MF. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82. PMID: 20605479.
      View in: PubMed
    70. Lee MH, Hammad SM, Semler AJ, Luttrell LM, Lopes-Virella MF, Klein RL. HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res. 2010 Sep; 51(9):2619-28. PMID: 20522601.
      View in: PubMed
    71. Wang B, Carter RE, Jaffa MA, Nakerakanti S, Lackland D, Lopes-Virella M, Trojanowska M, Luttrell LM, Jaffa AA. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet. 2010 Jun; 47(6):391-7. PMID: 20522428.
      View in: PubMed
    72. Li Y, Samuvel DJ, Sundararaj KP, Lopes-Virella MF, Huang Y. IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. J Cell Biochem. 2010 May; 110(1):248-59. PMID: 20225236.
      View in: PubMed
    73. Smith KJ, Twal WO, Soodavar F, Virella G, Lopes-Virella MF, Hammad SM. Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages. J Biol Chem. 2010 May 21; 285(21):15985-93. PMID: 20348092.
      View in: PubMed
    74. Samuvel DJ, Sundararaj KP, Li Y, Lopes-Virella MF, Huang Y. Adipocyte-mononuclear cell interaction, Toll-like receptor 4 activation, and high glucose synergistically up-regulate osteopontin expression via an interleukin 6-mediated mechanism. J Biol Chem. 2010 Feb 05; 285(6):3916-27. PMID: 20007708.
      View in: PubMed
    75. Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, Bharaj B, Sun L, Bull SB. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009 Nov; 29(11):1958-67. PMID: 19729612.
      View in: PubMed
    76. Fernandes JK, Wiegand RE, Salinas CF, Grossi SG, Sanders JJ, Lopes-Virella MF, Slate EH. Periodontal disease status in gullah african americans with type 2 diabetes living in South Carolina. J Periodontol. 2009 Jul; 80(7):1062-8. PMID: 19563285.
      View in: PubMed
    77. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65. PMID: 19427818.
      View in: PubMed
    78. Sundararaj KP, Samuvel DJ, Li Y, Sanders JJ, Lopes-Virella MF, Huang Y. Interleukin-6 released from fibroblasts is essential for up-regulation of matrix metalloproteinase-1 expression by U937 macrophages in coculture: cross-talking between fibroblasts and U937 macrophages exposed to high glucose. J Biol Chem. 2009 May 15; 284(20):13714-24. PMID: 19307187.
      View in: PubMed
    79. Samuvel DJ, Sundararaj KP, Nareika A, Lopes-Virella MF, Huang Y. Lactate boosts TLR4 signaling and NF-kappaB pathway-mediated gene transcription in macrophages via monocarboxylate transporters and MD-2 up-regulation. J Immunol. 2009 Feb 15; 182(4):2476-84. PMID: 19201903.
      View in: PubMed
    80. Brown WV, Clark L, Falko JM, Guyton JR, Rees TJ, Schonfeld G, Lopes-Virella MF. Optimal management of lipids in diabetes and metabolic syndrome. J Clin Lipidol. 2008 Oct; 2(5):335-42. PMID: 21291758.
      View in: PubMed
    81. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12. PMID: 18628568.
      View in: PubMed
    82. Sundararaj KP, Samuvel DJ, Li Y, Nareika A, Slate EH, Sanders JJ, Lopes-Virella MF, Huang Y. Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. J Leukoc Biol. 2008 Oct; 84(4):1120-9. PMID: 18625914.
      View in: PubMed
    83. Cole CM, Sundararaj KP, Leite RS, Nareika A, Slate EH, Sanders JJ, Lopes-Virella MF, Huang Y. A trend of increase in periodontal interleukin-6 expression across patients with neither diabetes nor periodontal disease, patients with periodontal disease alone, and patients with both diseases. J Periodontal Res. 2008 Dec; 43(6):717-22. PMID: 18627438.
      View in: PubMed
    84. Nareika A, Sundararaj KP, Im YB, Game BA, Lopes-Virella MF, Huang Y. High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. Atherosclerosis. 2009 Feb; 202(2):363-71. PMID: 18586252.
      View in: PubMed
    85. Virella G, Carter RE, Saad A, Crosswell EG, Game BA. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400. PMID: 18533284.
      View in: PubMed
    86. Hammad SM, Twal WO, Barth JL, Smith KJ, Saad AF, Virella G, Argraves WS, Lopes-Virella MF. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009 Feb; 202(2):394-404. PMID: 18597759.
      View in: PubMed
    87. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008 Oct; 200(2):239-46. PMID: 18513726.
      View in: PubMed
    88. Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab. 2008 May; 93(5):1893-900. PMID: 18319310.
      View in: PubMed
    89. Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55. PMID: 18202432.
      View in: PubMed
    90. Nareika A, Im YB, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor kappaB and AP-1 activities. J Endocrinol. 2008 Jan; 196(1):45-55. PMID: 18180316.
      View in: PubMed
    91. Carter RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella MF, Gilbert GE, Orchard TJ. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial. Diabetes Care. 2007 Oct; 30(10):2646-8. PMID: 17623823.
      View in: PubMed
    92. Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin. J Periodontal Res. 2007 Feb; 42(1):31-8. PMID: 17214637.
      View in: PubMed
    93. Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee D, McHenry MB, Lopes-Virella M, Garvey WT. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006 Sep; 23(9):955-66. PMID: 16922701.
      View in: PubMed
    94. Game BA, He L, Jarido V, Nareika A, Jaffa AA, Lopes-Virella MF, Huang Y. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis. 2007 May; 192(1):85-91. PMID: 16901490.
      View in: PubMed
    95. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006 Sep; 47(9):1975-83. PMID: 16804192.
      View in: PubMed
    96. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69. PMID: 16530770.
      View in: PubMed
    97. Hammad SM, Taha TA, Nareika A, Johnson KR, Lopes-Virella MF, Obeid LM. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat. 2006 Mar; 79(1-2):126-40. PMID: 16516816.
      View in: PubMed
    98. Yishak AA, Costacou T, Virella G, Zgibor J, Fried L, Walsh M, Evans RW, Lopes-Virella M, Kagan VE, Otvos J, Orchard TJ. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006 Jan; 21(1):93-100. PMID: 16144851.
      View in: PubMed
    99. Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug; 19(4):183-93. PMID: 15993351.
      View in: PubMed
    100. Nareika A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. Sodium lactate increases LPS-stimulated MMP and cytokine expression in U937 histiocytes by enhancing AP-1 and NF-kappaB transcriptional activities. Am J Physiol Endocrinol Metab. 2005 Oct; 289(4):E534-42. PMID: 15941782.
      View in: PubMed
    101. Lopes-Virella MF, Thorpe SR, Derrick MB, Chassereau C, Virella G. The immunogenicity of modified lipoproteins. Ann N Y Acad Sci. 2005 Jun; 1043:367-78. PMID: 16037258.
      View in: PubMed
    102. Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism. 2005 Apr; 54(4):453-9. PMID: 15798950.
      View in: PubMed
    103. Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005 Jan; 12(1):68-75. PMID: 15642987.
      View in: PubMed
    104. Costacou T, Zgibor JC, Evans RW, Otvos J, Lopes-Virella MF, Tracy RP, Orchard TJ. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2005 Jan; 48(1):41-8. PMID: 15616802.
      View in: PubMed
    105. Maldonado A, He L, Game BA, Nareika A, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. Pre-exposure to high glucose augments lipopolysaccharide-stimulated matrix metalloproteinase-1 expression by human U937 histiocytes. J Periodontal Res. 2004 Dec; 39(6):415-23. PMID: 15491346.
      View in: PubMed
    106. Virella G, Thorpe SR, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67. PMID: 15258197.
      View in: PubMed
    107. Lopes-Virella MF, Mironova M, Stephan E, Durazo-Arvizu R, Virella G. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004 Apr; 27(4):908-13. PMID: 15047647.
      View in: PubMed
    108. Vielma SA, Mironova M, Ku JR, Lopes-Virella MF. Oxidized LDL further enhances expression of adhesion molecules in Chlamydophila pneumoniae-infected endothelial cells. J Lipid Res. 2004 May; 45(5):873-80. PMID: 14967815.
      View in: PubMed
    109. Lopes-Virella MF, Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci. 2003 Sep 01; 8:s750-68. PMID: 12957881.
      View in: PubMed
    110. Game BA, Xu M, Lopes-Virella MF, Huang Y. Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones. Atherosclerosis. 2003 Aug; 169(2):235-43. PMID: 12921974.
      View in: PubMed
    111. Virella G, Lopes-Virella MF. Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol. 2003 Jul; 10(4):499-505. PMID: 12853376.
      View in: PubMed
    112. Fu Y, Huang Y, Bandyopadhyay S, Virella G, Lopes-Virella MF. LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1. J Lipid Res. 2003 Jul; 44(7):1315-21. PMID: 12730303.
      View in: PubMed
    113. Vielma SA, Krings G, Lopes-Virella MF. Chlamydophila pneumoniae induces ICAM-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappaB. Circ Res. 2003 May 30; 92(10):1130-7. PMID: 12714566.
      View in: PubMed
    114. Virella G, Lopes-Virella MF. Humoral immunity and atherosclerosis. Nat Med. 2003 Mar; 9(3):243-4; author reply 244-5. PMID: 12612552.
      View in: PubMed
    115. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 2002 Dec; 165(2):259-69. PMID: 12417276.
      View in: PubMed
    116. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003 Mar; 44(3):487-93. PMID: 12562876.
      View in: PubMed
    117. Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia. 2002 Nov; 45(11):1562-71. PMID: 12436340.
      View in: PubMed
    118. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002 Oct; 105(1):81-92. PMID: 12483997.
      View in: PubMed
    119. Vielma S, Virella G, Gorod A, Lopes-Virella M. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (FcgammaRII). Clin Immunol. 2002 Sep; 104(3):265-73. PMID: 12217337.
      View in: PubMed
    120. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, Vlassara H. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002 May 07; 105(18):e138-43. PMID: 11994264.
      View in: PubMed
    121. Anderson F, Game BA, Atchley D, Xu M, Lopes-Virella MF, Huang Y. IFN-gamma pretreatment augments immune complex-induced matrix metalloproteinase-1 expression in U937 histiocytes. Clin Immunol. 2002 Feb; 102(2):200-7. PMID: 11846463.
      View in: PubMed
    122. Fu Y, Luo N, Lopes-Virella MF. Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages. Atherosclerosis. 2002 Jan; 160(1):11-20. PMID: 11755918.
      View in: PubMed
    123. Song L, Xu M, Lopes-Virella MF, Huang Y. Quercetin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells through extracellular signal-regulated kinase. Arch Biochem Biophys. 2001 Jul 01; 391(1):72-8. PMID: 11414687.
      View in: PubMed
    124. Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis. 2001 May; 156(1):119-25. PMID: 11369004.
      View in: PubMed
    125. Takei A, Huang Y, Lopes-Virella MF. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis. 2001 Jan; 154(1):79-86. PMID: 11137085.
      View in: PubMed
    126. Klein RL, Ascenção JL, Mironova M, Huang Y, Lopes-Virella MF. Effect of inflammatory cytokines on the metabolism of low-density lipoproteins by human vascular endothelial cells. Metabolism. 2001 Jan; 50(1):99-106. PMID: 11172482.
      View in: PubMed
    127. Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2000 Dec; 20(12):2533-8. PMID: 11116049.
      View in: PubMed
    128. Fu Y, Luo N, Lopes-Virella MF. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J Lipid Res. 2000 Dec; 41(12):2017-23. PMID: 11108735.
      View in: PubMed
    129. Lopes-Virella MF, Koskinen S, Mironova M, Horne D, Klein R, Chassereau C, Enockson C, Virella G. The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis. 2000 Sep; 152(1):107-15. PMID: 10996345.
      View in: PubMed
    130. Thomas JC, Lopes-Virella MF, Del Bene VE, Cerveny JD, Taylor KB, McWhorter LS, Bultemeier NC. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000 Jun; 20(6):727-34. PMID: 10853629.
      View in: PubMed
    131. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41. PMID: 10866057.
      View in: PubMed
    132. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol. 2000 May; 95(2):135-44. PMID: 10779407.
      View in: PubMed
    133. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Nov; 19(11):2640-7. PMID: 10559006.
      View in: PubMed
    134. Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol. 1999 Jul; 19(7):1600-7. PMID: 10397676.
      View in: PubMed
    135. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1999 Jul; 48(7):1454-8. PMID: 10389853.
      View in: PubMed
    136. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72. PMID: 10080827.
      View in: PubMed
    137. Islam S, Gutin B, Treiber F, Hobbs G, Kamboh I, Lopes-Virella M. Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children. Arch Pediatr Adolesc Med. 1999 Jan; 153(1):57-62. PMID: 9895000.
      View in: PubMed
    138. Koskinen S, Enockson C, Lopes-Virella MF, Virella G. Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diagn Lab Immunol. 1998 Nov; 5(6):817-22. PMID: 9801341.
      View in: PubMed
    139. Willi SM, O'Rear D, Garvey WT, Colwell JA, Buse MG, Jaffa A, Lopes-Virella M, Wood D, Mayfield RK, Wallace P, Hermayer KL, Jenkins AJ, Lyons T, Mayer-Davis E. Diabetes research in South Carolina: past, present, and future. J S C Med Assoc. 1998 Nov; 94(11):502-8. PMID: 9844316.
      View in: PubMed
    140. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997 Dec; 135(2):161-70. PMID: 9430365.
      View in: PubMed
    141. Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol. 1997 Oct; 85(1):73-82. PMID: 9325072.
      View in: PubMed
    142. Huang Y, Ghosh MJ, Lopes-Virella MF. Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-containing immune complexes. J Lipid Res. 1997 Jan; 38(1):110-20. PMID: 9034205.
      View in: PubMed
    143. Lopes-Virella MF, Virella G. Modified lipoproteins, cytokines and macrovascular disease in non-insulin-dependent diabetes mellitus. Ann Med. 1996 Aug; 28(4):347-54. PMID: 8862690.
      View in: PubMed
    144. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 1996 Jul; 45 Suppl 3:S40-4. PMID: 8674888.
      View in: PubMed
    145. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 1996 Jun; 45(6):762-7. PMID: 8635650.
      View in: PubMed
    146. Lopes-Virella MF, Klein RL, Virella G. Modification of lipoproteins in diabetes. Diabetes Metab Rev. 1996 Apr; 12(1):69-90. PMID: 8861502.
      View in: PubMed
    147. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 1996 Feb; 16(2):222-9. PMID: 8620336.
      View in: PubMed
    148. Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes. 1995 Sep; 44(9):1093-8. PMID: 7657034.
      View in: PubMed
    149. Jokl R, Klein RL, Lopes-Virella MF, Colwell JA. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995 Aug; 18(8):1150-5. PMID: 7587850.
      View in: PubMed
    150. Virella G, Muñoz JF, Galbraith GM, Gissinger C, Chassereau C, Lopes-Virella MF. Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopathol. 1995 May; 75(2):179-89. PMID: 7704977.
      View in: PubMed
    151. Virella G, Mironova M, Lopes-Virella MF. Comparing assays of antibodies to modified low-density lipoproteins. Clin Chem. 1995 Feb; 41(2):324-5. PMID: 7874792.
      View in: PubMed
    152. Lopes-Virella MF, Virella G. Atherosclerosis and autoimmunity. Clin Immunol Immunopathol. 1994 Nov; 73(2):155-67. PMID: 7923923.
      View in: PubMed
    153. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994 Aug; 17(8):818-23. PMID: 7956624.
      View in: PubMed
    154. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J. 1993 Dec; 14 Suppl K:118-24. PMID: 8131779.
      View in: PubMed
    155. Klein RL, Lopes-Virella MF. Metabolism by human endothelial cells of very low density lipoprotein subfractions isolated from type 1 (insulin-dependent) diabetic patients. Diabetologia. 1993 Mar; 36(3):258-64. PMID: 8462776.
      View in: PubMed
    156. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993; 23(2):95-101. PMID: 8518420.
      View in: PubMed
    157. Klein RL, Wohltmann HJ, Lopes-Virella MF. Influence of glycemic control on interaction of very-low- and low-density lipoproteins isolated from type I diabetic patients with human monocyte-derived macrophages. Diabetes. 1992 Oct; 41(10):1301-7. PMID: 1397704.
      View in: PubMed
    158. Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes. 1992 Oct; 41 Suppl 2:86-91. PMID: 1526343.
      View in: PubMed
    159. Gisinger C, Lopes-Virella MF. Lipoprotein-immune complexes and diabetic vascular complications. Diabetes. 1992 Oct; 41 Suppl 2:92-6. PMID: 1526344.
      View in: PubMed
    160. Lopes-Virella MF, Virella G. Lipoproteins and immune responses in the vascular wall and their contribution to atherosclerosis in diabetes. Metabolism. 1992 May; 41(5 Suppl 1):11-5. PMID: 1574007.
      View in: PubMed
    161. Virella G, Fourspring K, Hyman B, Haskill-Stroud R, Long L, Virella I, La Via M, Gross AJ, Lopes-Virella M. Immunosuppressive effects of fish oil in normal human volunteers: correlation with the in vitro effects of eicosapentanoic acid on human lymphocytes. Clin Immunol Immunopathol. 1991 Nov; 61(2 Pt 1):161-76. PMID: 1833105.
      View in: PubMed
    162. Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1356-67. PMID: 1911721.
      View in: PubMed
    163. Gisinger C, Virella GT, Lopes-Virella MF. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopathol. 1991 Apr; 59(1):37-52. PMID: 2019010.
      View in: PubMed
    164. Lopes-Virella MF, Virella G. Immune mechanisms in the pathogenesis of atherosclerosis. Adv Exp Med Biol. 1991; 285:383-92. PMID: 1858570.
      View in: PubMed
    165. Klein RL, Lyons TJ, Lopes-Virella MF. Metabolism of very low- and low-density lipoproteins isolated from normolipidaemic type 2 (non-insulin-dependent) diabetic patients by human monocyte-derived macrophages. Diabetologia. 1990 May; 33(5):299-305. PMID: 2376301.
      View in: PubMed
    166. Klein RL, Lyons TJ, Lopes-Virella MF. Interaction of very-low-density lipoprotein isolated from type I (insulin-dependent) diabetic subjects with human monocyte-derived macrophages. Metabolism. 1989 Nov; 38(11):1108-14. PMID: 2554094.
      View in: PubMed
    167. Vaughn M, Virella G, Lopes-Virella MF. Diabetes, autoimmunity, and arteriosclerosis. Clin Immunol Immunopathol. 1989 Sep; 52(3):414-20. PMID: 2667823.
      View in: PubMed
    168. Marken PA, Weart CW, Carson DS, Gums JG, Lopes-Virella MF. Effects of magnesium oxide on the lipid profile of healthy volunteers. Atherosclerosis. 1989 May; 77(1):37-42. PMID: 2719760.
      View in: PubMed
    169. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes. 1988 Dec; 37(12):1652-7. PMID: 3192039.
      View in: PubMed
    170. Colwell JA, Lopes-Virella MF. A review of the development of large-vessel disease in diabetes mellitus. Am J Med. 1988 Nov 28; 85(5A):113-8. PMID: 3057888.
      View in: PubMed
    171. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988 Sep 01; 168(3):1041-59. PMID: 3171477.
      View in: PubMed
    172. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes. 1988 May; 37(5):550-7. PMID: 3129328.
      View in: PubMed
    173. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 1987 Dec; 30(12):916-23. PMID: 3436488.
      View in: PubMed
    174. Virella G, Lopes-Virella MF. Infections and atherosclerosis. Transplant Proc. 1987 Aug; 19(4 Suppl 5):26-35. PMID: 3303566.
      View in: PubMed
    175. Lopes-Virella MF, Colwell JA. Pharmacological treatment of lipid disorders in diabetes mellitus. Diabetes Metab Rev. 1987 Jul; 3(3):691-722. PMID: 3608755.
      View in: PubMed
    176. Lopes-Virella MF, Klein RL, Stevenson HC. Low density lipoprotein metabolism in human macrophages stimulated with microbial or microbial-related products. Arteriosclerosis. 1987 Mar-Apr; 7(2):176-84. PMID: 3107536.
      View in: PubMed
    177. Lopes-Virella MF. [Metabolism of lipoproteins in diabetes mellitus]. Journ Annu Diabetol Hotel Dieu. 1987; 55-66. PMID: 3302494.
      View in: PubMed
    178. Lyons TJ, Baynes JW, Patrick JS, Colwell JA, Lopes-Virella MF. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986 Oct; 29(10):685-9. PMID: 3803742.
      View in: PubMed
    179. Lopes-Virella MF, Virella G. Immunological and microbiological factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol. 1985 Dec; 37(3):377-86. PMID: 4053426.
      View in: PubMed
    180. Lopes-Virella MF, Sherer G, Wohltmann H, Sens D, Colwell JA. Diabetic lipoprotein deficient serum: its effect in low density lipoprotein (LDL) uptake and degradation by fibroblasts. Metabolism. 1985 Dec; 34(12):1079-85. PMID: 2999561.
      View in: PubMed
    181. Mayfield RK, Halushka PV, Wohltmann HJ, Lopes-Virella M, Chambers JK, Loadholt CB, Colwell JA. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33. PMID: 3930325.
      View in: PubMed
    182. Winocour PD, Lopes-Virella M, Laimins M, Colwell JA. Effect of insulin treatment in streptozocin-induced diabetic rats on in vitro platelet function and plasma von Willebrand factor activity and factor VIII-related antigen. J Lab Clin Med. 1985 Sep; 106(3):319-25. PMID: 3928783.
      View in: PubMed
    183. Lopes-Virella M. Abnormal metabolism of low density lipoprotein in diabetes mellitus. Horm Metab Res Suppl. 1985; 15:83-7. PMID: 3865886.
      View in: PubMed
    184. Colwell JA, Winocour PD, Lopes-Virella M, Halushka PV. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med. 1983 Nov 30; 75(5B):67-80. PMID: 6424441.
      View in: PubMed
    185. Winocour PD, Lopes-Virella M, Laimins M, Colwell JA. Time course of changes in in vitro platelet function and plasma von willebrand factor activity (VIIIR:WF) and factor VIII-related antigen (VIIIR:Ag) in the diabetic rat. J Lab Clin Med. 1983 Nov; 102(5):795-804. PMID: 6415193.
      View in: PubMed
    186. Virella G, Lopes-Virella MF, Shuler C, Sherwood T, Espinoza GA, Winocour P, Colwell JA. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. Immunology. 1983 Sep; 50(1):43-51. PMID: 6885111.
      View in: PubMed
    187. Lopes-Virella MF, Wohltmann HJ, Mayfield RK, Loadholt CB, Colwell JA. Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients. A longitudinal study. Diabetes. 1983 Jan; 32(1):20-5. PMID: 6336700.
      View in: PubMed
    188. Lopes-Virella MF, Sherer GK, Lees AM, Wohltmann H, Mayfield R, Sagel J, LeRoy EC, Colwell JA. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982 Jun; 22(6):430-6. PMID: 7049800.
      View in: PubMed
    189. Virella G, Wohltmann H, Sagel J, Lopes-Virella MF, Kilpatrick M, Phillips C, Colwell J. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia. 1981 Sep; 21(3):184-91. PMID: 7297792.
      View in: PubMed
    190. Lopes-Virella MF, Wohltmann HJ, Loadholt CB, Buse MG. Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: relationship with control. Diabetologia. 1981 Sep; 21(3):216-23. PMID: 7297793.
      View in: PubMed
    191. Colwell JA, Lopes-Virella M, Halushka PV. Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care. 1981 Jan-Feb; 4(1):121-33. PMID: 7009108.
      View in: PubMed
    192. Lopes-Virella MF, Virella G, Evans G, Malenkos SB, Colwell JA. Immunonephelometric assay of human apolipoprotein AI. Clin Chem. 1980 Jul; 26(8):1205-8. PMID: 6771058.
      View in: PubMed
    193. Gordon L, Mayfield RK, Levine JH, Lopes-Virella MF, Sagel J, Buse MG. Failure to visualize adrenal glands in a patient with bilateral adrenal hyperplasia. J Nucl Med. 1980 Jan; 21(1):49-51. PMID: 7356739.
      View in: PubMed
    194. Sagel J, Lopes-Virella MF, Levine JH, Colwell JA. Decreased high density lipoprotein cholesterol in hypopituitarism. J Clin Endocrinol Metab. 1979 Nov; 49(5):753-6. PMID: 226560.
      View in: PubMed
    195. Lopes-Virella M, Virella G, Debeukelaer M, Owens CJ, Colwell JA. Urinary high density lipoprotein in minimal change glomerular disease and chronic glomerulopathies. Clin Chim Acta. 1979 May 16; 94(1):73-81. PMID: 222512.
      View in: PubMed
    196. Lopes-Virella MF, Virella G, Rosebrock G, Sagel J, Gonzalez J, Colwell J. Early diagnosis of renal malfunction in diabetics. Abnormal proteinuria revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Diabetologia. 1979 Mar; 16(3):165-71. PMID: 428686.
      View in: PubMed
    197. Virella G, Munoz J, Lopes-Virella MF, Ward B, Gadsden R. Rapid immunochemical determination of free hemoglobin in plasma and urine with a laser nephelometer. Clin Chem. 1979 Mar; 25(3):497-9. PMID: 262203.
      View in: PubMed
    198. Colwell JA, Halushka PV, Sarji KE, Lopes-Virella MF, Sagel J. Vascular disease in diabetes: pathophysiological mechanisms and therapy. Arch Intern Med. 1979 Feb; 139(2):225-30. PMID: 434977.
      View in: PubMed
    199. Virella G, Lopes-Virella MF, Levine J, Ogawa M, Gonzalez J. "Idiopathic" Bence-Jones proteinuria. Acta Haematol. 1978; 60(5):269-79. PMID: 101013.
      View in: PubMed
    200. Virella G, Lopes-Virella MF. New approaches to the study of proteinuria. Clin Chem. 1977 Sep; 23(9):1793-4. PMID: 196787.
      View in: PubMed
    201. Lopes-Virella MF, Stone PG, Colwell JA. Serum high density lipoprotein in diabetic patients. Diabetologia. 1977 Aug; 13(4):285-91. PMID: 199515.
      View in: PubMed
    202. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977 May; 23(5):882-4. PMID: 192488.
      View in: PubMed
    203. Virella G, Monteiro JM, Lopes-Virella MF, Ducla Soares A, Fudenberg HH. Asynchronous development of two monoclonal proteins (IgM lambda and delta 1 chains) in a patient with abdominal lymphoma. Cancer. 1977 May; 39(5):2247-53. PMID: 404029.
      View in: PubMed
    204. Lopes-Virella MF, Sarji K, Virella G, Colwell JA. Platelet lipoproteins. A comparative study with serum lipoproteins. Biochim Biophys Acta. 1976 Aug 09; 439(2):339-48. PMID: 182240.
      View in: PubMed
    205. Lopes-Virella MF, Colwell JA. Serum-high-density-lipoprotein in diabetic patients. Lancet. 1976 Jun 12; 1(7972):1291-2. PMID: 73712.
      View in: PubMed
    206. Virella G, Lopes-Virella MF. Effects of therapeutically useful thiols (DL-penicillamine and alpha-mercaptopropionylglycine) on immunoglobulins. Clin Exp Immunol. 1970 Jul; 7(1):85-107. PMID: 4098291.
      View in: PubMed
    Lopes-Virella's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _